Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 04/02/2018
Entire Document
 
 

 

ONCOCYTE CORPORATION

STATEMENTS OF CASH FLOWS

(In thousands)

 

   Year Ended December 31 
   2017   2016   2015 
CASH FLOWS FROM OPERATING ACTIVITIES:               
Net loss  $(19,375)  $(11,168)  $(8,735)
Adjustments to reconcile net loss to net cash used in operating activities:               
Depreciation expense   338    145    41 
Amortization of intangible assets   242    242    242 
Stock-based compensation   1,630    922    1,815 
Loss on sale of available-for-sale securities, including selling commissions   309    -    - 
Warrants issued to certain shareholders as inducement to exercise of warrants   4,074    -    - 
Contingently issuable warrant expense to investors   -    -    65 
Amortization of debt issuance costs and interest expense   83    -    18 
Changes in operating assets and liabilities:               
Amount due to BioTime and affiliates   (753)   2,007    1,557 
Prepaid expenses and other current assets   115    101    (274)
Accounts payable and accrued liabilities   (48)   229    1,042 
Net cash used in operating activities   (13,385)   (7,522)   (4,229)
                
CASH FLOWS FROM INVESTING ACTIVITIES:               
Net proceeds from sale of available-for-sale securities   934    -    815 
Purchase of equipment   (91)   (106)   (500)
Security deposit   -    (75)   - 
Net cash provided by (used in) investing activities   843    (181)   315 
                
CASH FLOWS FROM FINANCING ACTIVITIES:               
Proceeds from exercise of options   610    218    4 
Proceeds from exercise of warrants   7,774    -    - 
Proceeds from sale of common stock   -    -    11,649 
Proceeds from sale of common stock and warrants   -    10,550    - 
Financing costs related to sale of common stock and warrants   -    (773)   - 
Proceeds from issuance of loan payable, net of financing costs   1,982    -    - 
Repayment of loan payable   (133)   -    - 
Repayment of capital lease obligation   (265)   (114)   - 
Net cash provided by financing activities   9,968    9,881    11,653 
                
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS   (2,574)   2,178    7,739 
CASH AND CASH EQUIVALENTS:               
At beginning of the year   10,174    7,996    257 
At end of the year  $7,600   $10,174   $7,996 
                
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION               
Cash paid for interest  $130   $29   $- 
                
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES               
Equipment purchased under capital leases  $381   $626   $- 
Debt issuance costs   196    -    - 
Common stock issued to BioTime for extinguishment of debt   -    -    3,300 
Common stock issued to BioTime upon conversion of convertible note payable and accrued interest   -    -    3,318 
Realized loss on sale of BioTime shares   -    -    397 

 

The accompanying notes are an integral part of these financial statements.

 

   

© Copyright BioTime, Inc.